Key Points
- Insider sale: Director Shannon Morris sold 20,000 shares of Erasca on March 4 at an average price of $15.04, totaling $300,800, as disclosed in an SEC filing.
- Share-price context: ERAS opened at $15.47 (near its one-year high of $16.00), with a 50-day/200-day simple moving average of $10.11/$5.09 and a market capitalization of about $4.79 billion.
- Analyst and ownership backdrop: Ratings are mixed — consensus is a "Moderate Buy" with a consensus price target of $9.22 (below current price) — and institutional investors own roughly 67.8% of the stock.
Erasca, Inc. (NASDAQ:ERAS - Get Free Report) insider Shannon Morris sold 20,000 shares of Erasca stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $15.04, for a total value of $300,800.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Erasca Trading Down 0.5%
Shares of NASDAQ ERAS opened at $15.47 on Friday. The business has a fifty day simple moving average of $10.11 and a 200 day simple moving average of $5.09. The firm has a market capitalization of $4.79 billion, a price-to-earnings ratio of -34.38 and a beta of 1.16. Erasca, Inc. has a one year low of $1.01 and a one year high of $16.00.
Wall Street Analyst Weigh In
ERAS has been the subject of a number of recent research reports. Morgan Stanley set a $10.00 price objective on shares of Erasca in a research note on Monday, January 26th. HC Wainwright lifted their target price on shares of Erasca from $11.00 to $15.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Mizuho began coverage on shares of Erasca in a research note on Tuesday, January 27th. They issued an "outperform" rating and a $16.00 target price on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Erasca in a research report on Thursday, January 22nd. Finally, Guggenheim restated a "buy" rating and set a $12.00 price target on shares of Erasca in a research note on Tuesday, January 27th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.22.
Get Our Latest Report on ERAS
Institutional Investors Weigh In On Erasca
A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its position in Erasca by 58.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company's stock valued at $27,000 after purchasing an additional 7,923 shares during the last quarter. EP Wealth Advisors LLC bought a new stake in shares of Erasca during the second quarter worth $29,000. Russell Investments Group Ltd. acquired a new stake in shares of Erasca in the third quarter valued at $31,000. SG Americas Securities LLC bought a new position in shares of Erasca in the third quarter valued at about $32,000. Finally, Crowley Wealth Management Inc. bought a new position in shares of Erasca in the third quarter valued at about $33,000. 67.78% of the stock is currently owned by institutional investors.
About Erasca
(
Get Free Report)
Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca's approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.
Erasca's pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
